mild cognitive impairment.
Conditions
Interventions
hypothermia stimulation group:hypothermia stimulation
control group:Normal temperature stimulation
Sponsors
Xuanwu Hospital Capital Medical University
Eligibility
Sex/Gender
All
Age
65 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Eligible participants are adults aged 65 to 80 years, inclusive of both sexes. 2. Patients, healthcare professionals, or informants report alterations in cognitive functions, including memory, that have persisted for a period of at least three months. (Documentation of progressive cognitive decline over time, as ascertained through medical records or clinical assessments) . 3. In accordance with the diagnostic criteria outlined in the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), the individual does not fulfill the criteria for cognitive normality or dementia. However, the capacity for activities of daily living is within the normal range, as evidenced by a Mini-Mental State Examination (MMSE) score of >= 20 for individuals with primary education or >= 24 for those with junior education or higher, and a Montreal Cognitive Assessment (MoCA) score of <= 26, along with a Clinical Dementia Rating (CDR) of <= 1. 4. Have fully comprehended the details of the research protocol and signed the informed consents.
Exclusion criteria
Exclusion criteria: 1. Inability to understand the text, combined with a severe physical disability, or any other factor that may prevent completion of the neuropsychological assessment; 2. Any neoplastic disease (including polycythemia); 3. Clinically significant cardiovascular and cerebrovascular diseases, pulmonary diseases, liver diseases, kidney diseases, autoimmune or inflammatory diseases, metabolic and endocrine disorders, and severe neuropsychiatric diseases, such as AD, FTD, LBD, PD, schizophrenia, severe depression, epilepsy, etc.; 4. History of alcohol or drug abuse; Use of other drugs that may affect this study, such as sedatives, anti-anxiety drugs, hypnotics, nootropic drugs, cholinoid drugs; 5. Receive other acoustic, photoelectric and magnetic stimulation within a year; 6. Patients with Raynaud disease; 7. Cochlear implants, implanted electrodes, pacemakers or metal implants; 8. The assessment of daily living ability, mental state and social participation ability or sensory perception and communication ability indicates impaired function; 9. Life expectancy <1 year; 10. Poor compliance or inability to complete complete treatment; 11. The researcher believes that there are some circumstances that are inappropriate to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The changes of oxygen saturation of local brain tissue in the forehead; | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical cognitive function and symptom scores in each cognitive domain;Sleep status change;Clinical endpoint event;Local skin damage caused by hypothermic stimulation during treatment;body temperature changes; | — |
Countries
China
Contacts
Public ContactHaiqing Song
Xuanwu Hospital Capital Medical University
Outcome results
None listed